Every 10-Q that Genelux Corporation (GNLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GNLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNLX filings page.
Genelux Corporation, a late clinical-stage oncology biotech, reported no revenue and a larger net loss as it advances its lead oncolytic virus candidate Olvi-Vec. Net loss was $9.5 million for the quarter and $18.4 million for the first half of 2026, driven mainly by higher research and development spending.
R&D expenses rose to $12.3 million for the six months, largely from the Phase 3 On Prime/GOG-3076 registration trial, while general and administrative costs were $6.5 million. Cash, cash equivalents, restricted cash and marketable securities totaled $18.7 million at June 30, 2026, after a $18.5 million underwritten equity offering and modest ATM sales.
The company discloses substantial doubt about its ability to continue as a going concern, given recurring losses and cash used in operations of $12.5 million in the first half. Management currently expects existing funds to support planned operations into the first quarter of 2027 and anticipates needing additional financing to complete development and potential commercialization of Olvi-Vec.
Genelux Corporation is a late clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies and remains pre‑revenue, reporting a net loss of $8.9 million for the quarter ended March 31, 2026, compared with $7.5 million a year earlier.
Operating expenses rose to $9.2 million, driven mainly by higher research and development spending as the company advances its Olvi‑Vec program, including a Phase 3 trial. Cash, cash equivalents, restricted cash and marketable securities totaled $26.3 million, bolstered by a January 2026 equity offering that raised $18.5 million.
The company’s auditors and management highlight substantial doubt about its ability to continue as a going concern, as Genelux has an accumulated deficit of $292.5 million and expects continued losses. Management currently expects existing funds to support planned operations into the first quarter of 2027.
Genelux Corporation (GNLX) filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Net loss was $7.95 million for the quarter and $22.9 million for the nine months ended September 30, 2025, as the company recorded $8.2 million in quarterly operating expenses driven by R&D and G&A.
Liquidity remains constrained: cash, cash equivalents, restricted cash and short‑term investments totaled $21.0 million as of September 30, 2025, and net cash used in operations was $19.1 million for the nine months. Management states these resources are expected to fund operations into the third quarter of 2026. The independent auditor previously expressed substantial doubt about the company’s ability to continue as a going concern.
Genelux completed a March 2025 underwritten offering of 3,000,000 shares at $3.50, yielding $9.6 million in net proceeds, and issued an underwriter warrant for 120,000 shares at $4.20. Shares outstanding were 38,046,778 as of September 30, 2025. The company continues advancing Olvi‑Vec, including a Phase 2 NSCLC trial under its Newsoara collaboration.